Nichi-Iko Records Double-digit Growth For 3Q
This article was originally published in PharmAsia News
Nichi-Iko reported generic drug sales grew by 16.8 percent to ¥46.9 billion for the third quarter ending Aug. 31. Net profit also increased by 2.7 percent to ¥2.7 billion
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.